All enrolled patients who been given a minimum of a single dose of zosuquidar or placebo through induction ended up monitored for that event of adverse activities (439 individuals, 219 on zosuquidar and 210 on placebo). The commonest adverse events were being associated with the duration of prolonged and significant https://fionag544sdo6.wikirecognition.com/user